DaVita (DVA)
(Delayed Data from NYSE)
$139.68 USD
+1.96 (1.42%)
Updated Jul 17, 2024 04:00 PM ET
After-Market: $139.70 +0.02 (0.01%) 6:38 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.68 USD
+1.96 (1.42%)
Updated Jul 17, 2024 04:00 PM ET
After-Market: $139.70 +0.02 (0.01%) 6:38 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.
New Strong Buy Stocks for March 14th
by Zacks Equity Research
IMMR, NVR, SKWD, DVA and APAM have been added to the Zacks Rank #1 (Strong Buy) List on March 14, 2024.
Chemed's (CHE) VITAS Segment Inks New Deal With Covenant Care
by Zacks Equity Research
Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.
Best Value Stocks to Buy for March 14th
by Zacks Equity Research
IMXI, SKWD and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 14, 2024.
AMN Healthcare (AMN) Expands Capabilities of ShiftWise Flex
by Zacks Equity Research
AMN Healthcare's (AMN) expansion of the capabilities of ShiftWise Flex is likely to enhance internal resource pool management for the healthcare system.
Philips (PHG), AWS Unite to Scale Digital Pathology Solutions
by Zacks Equity Research
Philips (PHG) collaborates with Amazon Web Services to boost cloud-based pathology solutions. It will enable pathology laboratories to use digital processes to improve analytical capabilities.
PacBio's (PACB) New Panel to Aid Its Clinical Research Solution
by Zacks Equity Research
PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.
Alcon's (ALC) New Launch Strengthens IOL Innovation Leadership
by Zacks Equity Research
Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.
Philips (PHG) Aids Personal Health Business With New Campaign
by Zacks Equity Research
Philips (PHG) launches #ShareTheCare brand positioning campaign for Philips Avent, bolstering the Personal Health segment.
ClearPoint's (CLPT) Prism System Favored by Latest Study
by Zacks Equity Research
ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.
Here's Why You Should Retain BD (BDX) to Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.
Bruker (BRKR) Announces Advanced timsTOF Solutions at US HUPO
by Zacks Equity Research
Bruker (BRKR) advances CCS-Enabled 4D-Proteomics timsTOF solutions for immunopeptidomes and glycoproteomics at the US HUPO 2024.
GE HealthCare (GEHC) AI Model to Predict Immunotherapy Response
by Zacks Equity Research
GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.
Thermo Fisher (TMO) Unveils CorEvitas Clinical Registry in GPP
by Zacks Equity Research
Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.
Cardinal Health (CAH) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Cigna (CI) Unveils Updated Long-Term Growth Targets & Solutions
by Zacks Equity Research
Cigna (CI) currently estimates long-term average annual adjusted EPS growth within 10-14%. It also came up with new solutions to better manage the rising GLP-1 costs and expand behavioral care.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System
by Zacks Equity Research
DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.
Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone
by Zacks Equity Research
Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.